[go: up one dir, main page]

AR115881A1 - IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS - Google Patents

IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS

Info

Publication number
AR115881A1
AR115881A1 ARP190102171A ARP190102171A AR115881A1 AR 115881 A1 AR115881 A1 AR 115881A1 AR P190102171 A ARP190102171 A AR P190102171A AR P190102171 A ARP190102171 A AR P190102171A AR 115881 A1 AR115881 A1 AR 115881A1
Authority
AR
Argentina
Prior art keywords
peptides
refers
combination
against cancer
immunotherapy
Prior art date
Application number
ARP190102171A
Other languages
Spanish (es)
Inventor
Toni Weinschenk
Jens Fritsche
Oliver Schoor
Daniel Kowalewski
Heiko Schuster
Michael Rmer
Gisela Schimmack
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR115881A1 publication Critical patent/AR115881A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente se refiere a la inmunoterapia contra el cáncer. La presente se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antimorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.This refers to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, this refers to immunotherapy against cancer. The present also refers to peptide epitopes for tumor-associated T lymphocytes, alone or in combination with other tumor-associated peptides that, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antimoral immune responses, or to stimulate ex vivo. T lymphocytes that will later be transferred to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.

ARP190102171A 2018-07-31 2019-07-31 IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS AR115881A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102018118550 2018-07-31

Publications (1)

Publication Number Publication Date
AR115881A1 true AR115881A1 (en) 2021-03-10

Family

ID=75905104

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102171A AR115881A1 (en) 2018-07-31 2019-07-31 IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS

Country Status (1)

Country Link
AR (1) AR115881A1 (en)

Similar Documents

Publication Publication Date Title
CL2023001346A1 (en) Use of peptides in immunotherapy against small cell lung cancer and others.
CL2021002459A1 (en) Peptides and peptide combinations for use in cancer immunotherapy (divisional of application no. 201902093)
CL2021000842A1 (en) Peptides and peptide combinations of non-canonical origin for use in immunotherapy against different types of cancer. (divisional application no. 202002123)
CO2018008763A2 (en) Peptides, combinations of peptides and cells for use in immunotherapy against urinary bladder cancer and other types of cancer
CO2021000534A2 (en) Immunotherapy with b * 07-restricted peptides and a combination of anticancer peptides and related methods
CR20200560A (en) PEPTIDES AND PEPTID COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST NON-HADGKINIAN LYMPHOMA (NHL) AND OTHER TYPES OF CANCER (Divisional 2018-0346)
CR20210038A (en) UTERAL CANCER TREATMENT (Divisional 2018-0460)
CO2019012077A2 (en) Peptides and combinations thereof for use in immunotherapy against various types of cancer
CO2021004270A2 (en) B * 44 Restricted Peptides for Use in Cancer Immunotherapy and Related Methods
CO2021003404A2 (en) Immunotherapy with a * 01-restricted peptides and a combination of anticancer peptides and related methods
CL2022003381A1 (en) a*03-restricted peptides, use in cancer immunotherapy and related methods (split application 202003371)
CO2020013652A2 (en) Peptides for use in cancer immunotherapy
CL2021000177A1 (en) Peptides, peptide combinations, cells and kits for use in cancer immunotherapy (divisional application no. 201802360)
CL2021001336A1 (en) Immunotherapy with b * 08 restricted peptides and a combination of anticancer peptides and related methods
AR115881A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS
AR117437A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 08 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS
AR114736A1 (en) PEPTIDES RESTRICTED BY B * 44 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS
AR114532A1 (en) PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER
AR115254A1 (en) PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal